Dopamine neurotransmission and treatments for Parkinson's disease in the molecular biology era.
The study of dopamine neurotransmission has seen remarkable progress during the past quarter of a century. However, new problems keep arising as more is learned from biochemical analytical studies, necessitating even more detailed investigation in order to understand the relationship between dopamine neurotransmission and motor functions. For better treatment of Parkinson's disease, it is important to solve these problems.
Ogawa
N
N
Department of Neuroscience, Okayama University Medical School, Japan. ogawnkun@cc.okayama-u.ac.jp
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy / Q000628:therapy*; D009435:Synaptic Transmission / Q000502:physiology*
D000978:Antiparkinson Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D018491:Dopamine Agonists; D004791:Enzyme Inhibitors; D007980:Levodopa; D004298:Dopamine